From Inc · · 1m 30s
OpenAI and Peter Thiel Bet $45M on Brain Implant for Cancer
OpenAI and Peter Thiel join $45m investment in brain implant startup targeting cancer treatment.
In brief
OpenAI and Peter Thiel join $45m investment in brain implant startup targeting cancer treatment. OpenAI's Startup Fund and Peter Thiel's Founders Fund invested $45 million in Coherence, a company developing brain implants to detect and treat cancer. Originally reported by Inc.
OpenAI and Peter Thiel Join Investment
OpenAI's Startup Fund and Peter Thiel's Founders Fund joined a $45 million seed round for cancer detecting brain implant company Coherence.
Coherence's Brain Implant Technology
Coherence's SOMA implant monitors cancerous tumors' electrical signals and emits stimulation to stave off development.
First Clinical Trial Focus
The first application targets glioblastoma, an aggressive brain cancer that killed senators john mccain and ted kennedy.
FDA Breakthrough Device Goal
Coherence seeks FDA breakthrough device designation for glioblastoma treatment and expands pre-clinical trials for pancreatic cancer.
Investment Backers Include Neuralink
The investment includes participation from Lux Capital, 8VC, Neuralink's head neurosurgeon, and others.
Coherence Co-Founders Explain
Coherence co-founders ben woodington and elise jenkins founded the company in 2022 to leverage neuroscience and technology for cancer therapy.
SOMA Implant Functionality
The SOMA implant pairs with a coin-sized wearable and app for real-time data, symptom tracking, and therapy history.
Clinical Testing Progress
Coherence has initiated safety testing by placing implants in patients' brains for 30 minutes during surgeries.
Cancer Treatment Potential
The technology could have applications across the body using continuous patient data to train ai algorithms.
The takeaway
OpenAI's Startup Fund and Peter Thiel's Founders Fund invested $45 million in Coherence, a company developing brain implants to detect and treat cancer.
